Comparative Safety Profiles of Baricitinib and Tofacitinib in the Treatment of Adult Alopecia Areata: A Pharmacovigilance Study Based on the FAERS Database

January 2026 in “ Frontiers in Public Health ”

Lingsong Kong, Xu Liu, Yanhuan Feng

baricitinib tofacitinib alopecia areata FAERS pharmacovigilance AA

TLDR Baricitinib and tofacitinib have different safety patterns in treating alopecia areata.

A pharmacovigilance study using the FAERS database compared the safety profiles of baricitinib and tofacitinib in treating adult alopecia areata (AA). The study found distinct post-marketing safety signal patterns for each drug, likely due to their different regulatory indications and real-world use. These findings are considered hypothesis-generating and suggest the need for clinical vigilance and future analytical studies. Prospective research with controlled exposure data is necessary to validate the identified safety signals.

View this study on public-pages-files-2025.frontiersin.org →

Discuss this study in the Community →

Research cited in this study

9 / 9 results

Efficacy and Safety of the Oral Janus Kinase Inhibitor Baricitinib in the Treatment of Adults with Alopecia Areata: Phase 2 Results from a Randomized Controlled Study

research Efficacy and Safety of the Oral Janus Kinase Inhibitor Baricitinib in the Treatment of Adults with Alopecia Areata: Phase 2 Results from a Randomized Controlled Study

66 citations , June 2021 in “Journal of The American Academy of Dermatology”

Baricitinib is effective and safe for treating severe alopecia areata.

research Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study

66 citations , December 2018 in “Dermatology”

Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.

research Alopecia Areata: Treatment Options and Efficacy

182 citations , December 2017 in “Journal of the American Academy of Dermatology”

Some treatments can help with a hair loss condition called alopecia areata, but none ensure lasting results; choices depend on the person, with JAK inhibitors showing promise for severe cases.

research Tofacitinib 2% Ointment, a Topical Janus Kinase Inhibitor, for the Treatment of Alopecia Areata: A Pilot Study of 10 Patients

48 citations , November 2017 in “Journal of the American Academy of Dermatology”

Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.

research JAK Inhibitors in Dermatology: The Promise of a New Drug Class

355 citations , January 2017 in “Journal of the American Academy of Dermatology”

JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.

research Safety and Efficacy of the JAK Inhibitor Tofacitinib Citrate in Patients with Alopecia Areata

222 citations , September 2016 in “JCI insight”

Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.

research Epidemiology and Burden of Alopecia Areata: A Systematic Review

144 citations , July 2015 in “Clinical, Cosmetic and Investigational Dermatology”

Alopecia areata is a common autoimmune disease affecting about 2% of people, causing significant disability and often associated with mental health issues and other autoimmune conditions.

research The Autoimmune Basis of Alopecia Areata: A Comprehensive Review

162 citations , October 2014 in “Autoimmunity reviews”

Alopecia areata is caused by the immune system attacking hair follicles.

research Inhibiting Janus Kinases to Treat Alopecia Areata

52 citations , September 2014 in “Nature medicine”

JAK inhibitors might help treat alopecia areata.

Related Community Posts Join

6 / 19 results

Compressed part of research of theory of androgenic/anabolitic balance. AGA h-responders analytic. Theory of physio-metabolitic method of anti AGA treatment

community Compressed part of research of theory of androgenic/anabolitic balance. AGA h-responders analytic. Theory of physio-metabolitic method of anti AGA treatment

MagicBold in Research 865 upvotes 1 year ago

The treatment for androgenetic alopecia involves using finasteride and minoxidil with intense exercise and cold exposure to boost metabolism and reduce androgenic effects, potentially leading to hair regrowth. This approach may activate biological pathways for improved hair and overall health.

community What else is good. Besides the big 3.

in Chat 35 upvotes 1 year ago

Key treatments for hair preservation include minoxidil, finasteride/dutasteride, and microneedling, with additional options like specific shampoos, oils, biotin, zinc, tretinoin, clascoterone, and low-level laser therapy. Maintaining a healthy lifestyle, reducing stress, and addressing nutrient deficiencies can also support hair health.

community Olumiant alternative for Alopecia Areata?

in Treatment 1 upvotes 2 years ago

A user with alopecia areata is considering treatment options like injections or Olumiant but is concerned about cost and whether delaying treatment will lead to permanent hair loss. They are seeking alternative treatments that are more affordable for a college student.

community What are the odds baricitinib will get a topical otc version for androgenic alopecia?

in Research/Science 3 years ago

Baricitinib, approved for alopecia areata, might be considered for treating receding hairlines. The discussion is about the possibility of an over-the-counter topical version for androgenic alopecia.

community Covid (likely) induced alopecia areata - now 2nd round of Covid, what can I expect?

in Treatment 1 upvotes 3 years ago

After experiencing hair loss due to alopecia areata following COVID-19 vaccination and infection, the individual saw improvement with steroid treatments and Olumiant. They paused Olumiant during a second COVID-19 infection and expressed concern about potential hair loss flare-ups.

community Olumiant active ingredient Baricitinib

in Research/Science 1 upvotes 3 years ago

The conversation is about someone inquiring if anyone has tried Olumiant or its active ingredient, Baricitinib, for hair loss, mentioning the cost and that they have ordered Baricitinib.

Similar Research

5 / 699 results

research Upadacitinib Therapy in Adolescent Severe Alopecia Areata: A Case Series and Narrative Review

1 citations , September 2025 in “Clinical Cosmetic and Investigational Dermatology”

Upadacitinib is effective and safe for treating severe Alopecia Areata in adolescents.

Technological Advances in Anti-Hair Loss and Hair Regrowth Cosmeceuticals: Mechanistic Breakthroughs and Industrial Prospects Driven by Multidisciplinary Collaborative Innovation

research Technological Advances in Anti-Hair Loss and Hair Regrowth Cosmeceuticals: Mechanistic Breakthroughs and Industrial Prospects Driven by Multidisciplinary Collaborative Innovation

August 2025 in “Aesthetic Plastic Surgery”

Collaboration and innovation are key to developing effective, safe hair loss treatments.

Unmet Medical Needs in Chronic, Non-Communicable Inflammatory Skin Diseases